Chenfei Wang is a managing director in the firm’s strategic advisory business. Based in Beijing, China, he focuses on Asia cross-border activities across the consumer, healthcare, industrial and technology sectors.
Notable transactions of Mr. Wang include advising HUTCHMED on the out-licensing of ex-China rights of Fruquintinib to Takeda; GNC on the sale of its assets to Harbin Pharmaceuticals; Sinocare on its acquisitions of Nipro Diagnostics and PTS Diagnostics; the special committee of Hilton on a 25% investment from HNA Group; Francisco Partners on the sale of Source Photonics to a Chinese consortium; and Envisics on its strategic funding round involving SAIC, Hyundai Mobis, GM and Van Tuyl Companies.
Prior to joining Evercore in 2014, Mr. Wang began his career in the leveraged acquisition & finance group at HSBC Securities in New York.
He received a B.S. in finance from Indiana University. He is a native Mandarin speaker.